85 related articles for article (PubMed ID: 25224479)
1. Routine use of maintenance therapy in follicular lymphoma: examine the rationale for maintenance use before uniformly adopting a strategy.
Flowers CR
Oncology (Williston Park); 2014 Sep; 28(9):787, 793. PubMed ID: 25224479
[No Abstract] [Full Text] [Related]
2. Routine use of maintenance therapy in follicular lymphoma: the strategy is effective, raising the question, 'what is the most important measure of success in the current era?'.
Nastoupil LJ
Oncology (Williston Park); 2014 Sep; 28(9):786, 793. PubMed ID: 25224478
[No Abstract] [Full Text] [Related]
3. Maintenance therapy in follicular lymphoma.
Michallet AS; Coiffier B; Salles G
Curr Opin Oncol; 2011 Sep; 23(5):449-54. PubMed ID: 21734580
[TBL] [Abstract][Full Text] [Related]
4. Rituximab maintenance in follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2015 Mar; 13(3):158-61. PubMed ID: 26352422
[No Abstract] [Full Text] [Related]
5. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183
[TBL] [Abstract][Full Text] [Related]
6. Rethinking Prognosis and Therapy for Follicular Lymphoma.
Jacobson CA; Freedman AS
J Clin Oncol; 2015 Aug; 33(23):2489-91. PubMed ID: 26169620
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Ribrag V; Tilly H; Casasnovas O; Bosly A; Bouabdallah R; Delarue R; Boue F; Bron D; Feugier P; Haioun C; Offner F; Coiffier B
Eur J Cancer; 2013 Mar; 49(4):904-10. PubMed ID: 23273434
[TBL] [Abstract][Full Text] [Related]
9. Follicular non-Hodgkin's lymphoma: the role of radiation therapy.
Mauch P
Ann Hematol; 2001; 80 Suppl 3():B63-5. PubMed ID: 11757711
[No Abstract] [Full Text] [Related]
10. [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
Palacios Abufón A; Acebo Mariñas E; Gardeazabal García J; García-Ruiz JC
Actas Dermosifiliogr; 2012 Apr; 103(3):253-5. PubMed ID: 22093542
[No Abstract] [Full Text] [Related]
11. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.
Rohatiner A; Radford J; Deakin D; Earl H; Love SB; Price O; Wilson A; Lister TA
Br J Cancer; 2001 Jul; 85(1):29-35. PubMed ID: 11437398
[TBL] [Abstract][Full Text] [Related]
12. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
[TBL] [Abstract][Full Text] [Related]
13. Rituximab maintenance versus retreatment in follicular lymphoma.
Palla AR; Hamadani M
Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
[TBL] [Abstract][Full Text] [Related]
14. Follicular lymphoma, survival, and rituximab: is it time to declare victory?
Horning SJ
J Clin Oncol; 2008 Oct; 26(28):4537-8. PubMed ID: 18662966
[No Abstract] [Full Text] [Related]
15. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study.
Witzens-Harig M; Foá R; Di Rocco A; van Hazel G; Chamone DF; Rowe JM; Arcaini L; Poddubnaya I; Ho AD; Ivanova V; Vranovsky A; Thurley D; Oertel S
Ann Hematol; 2014 Oct; 93(10):1717-24. PubMed ID: 24824768
[TBL] [Abstract][Full Text] [Related]
16. A renaissance for autologous transplantation in follicular lymphoma?
Chaekal OK; van Besien K
Leuk Lymphoma; 2019 Jan; 60(1):3-5. PubMed ID: 29966478
[No Abstract] [Full Text] [Related]
17. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
18. New agents in follicular lymphoma.
Cheson BD
Best Pract Res Clin Haematol; 2011 Jun; 24(2):305-12. PubMed ID: 21658626
[TBL] [Abstract][Full Text] [Related]
19. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
20. [Standard therapy and research questions in follicular lymphoma].
Ishizawa K
Rinsho Ketsueki; 2012 Oct; 53(10):1624-33. PubMed ID: 23037735
[No Abstract] [Full Text] [Related]
[Next] [New Search]
